Drug Profile
Research programme: tankyrase inhibitors - Domainex/Breakthrough Breast Cancer Research Centre/ICR
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Breakthrough Breast Cancer; Domainex; The Institute of Cancer Research
- Developer Domainex; The Institute of Cancer Research
- Class Small molecules
- Mechanism of Action Tankyrase inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in United Kingdom
- 20 Mar 2009 Early research in Breast cancer in United Kingdom (unspecified route)